INCYTE
Incyte 2013 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation.

News
Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies
Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information
Pivotal Phase III Data in Polycythemia Vera Show that Jakafi® (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies
Jakafi® (ruxolitinib)
IncyteCARES
Connecting to Access, Reimbursement, Education and Support
To learn more, click here